WEAV vs TMDX vs SCHW vs AVXL vs NVCR

For growth investors, TransMedics Group, Inc.

(TMDX) is the stronger pick with 37. 1% revenue growth year-over-year, versus 1. 9% for The Charles Schwab Corporation (SCHW). TransMedics Group, Inc. (TMDX) offers the better valuation at 15. 0x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Weave Communications, Inc. (WEAV) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TransMedics Group, Inc.

(TMDX) is the cheapest at 15. 0x versus The Charles Schwab Corporation at 29. 9x. On forward P/E, The Charles Schwab Corporation is actually cheaper at 14. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, TransMedics Group, Inc.

(TMDX) delivered a total return of +200. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: SCHW returned +255. 2% versus WEAV's -67. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Charles Schwab Corporation (SCHW) is the lower-risk stock at 0.

72β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 204% more volatile than SCHW relative to the S&P 500. On balance sheet safety, NovoCure Limited (NVCR) carries a lower debt/equity ratio of 85% versus 105% for Weave Communications, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TransMedics Group, Inc.

(TMDX) is pulling ahead at 37. 1% versus 1. 9% for The Charles Schwab Corporation (SCHW). On earnings-per-share growth, the picture is similar: TransMedics Group, Inc. grew EPS 382. 2% year-over-year, compared to -3. 8% for Anavex Life Sciences Corp.. Over a 3-year CAGR, TMDX leads at 86. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TransMedics Group, Inc.

(TMDX) is the more profitable company, earning 31. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SCHW leads at 29. 6% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — SCHW leads at 75. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Charles Schwab Corporation (SCHW) trades at 14.

9x forward P/E versus 36. 2x for Weave Communications, Inc. — 21. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVXL: 252. 6% to $11. 00.

In this comparison, SCHW (1.

4% yield) pays a dividend. WEAV, TMDX, AVXL, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Charles Schwab Corporation (SCHW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

72), 1. 4% yield, +255. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SCHW: +255. 2%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WEAV (Technology) and TMDX (Healthcare) and SCHW (Financial Services) and AVXL (Healthcare) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WEAV is a small-cap high-growth stock; TMDX is a small-cap high-growth stock; SCHW is a mid-cap quality compounder stock; AVXL is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. SCHW pays a dividend while WEAV, TMDX, AVXL, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.